{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T20:42:38Z","timestamp":1793565758312,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["CU-GIF_62_05_33_01"],"award-info":[{"award-number":["CU-GIF_62_05_33_01"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.xphs.2021.04.021","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T03:40:22Z","timestamp":1620704422000},"page":"3118-3128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control"],"prefix":"10.1016","volume":"110","author":[{"given":"Bodin","family":"Tuesuwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-7506","authenticated-orcid":false,"given":"Vorasit","family":"Vongsutilers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2021.04.021_bib0001","doi-asserted-by":"crossref","unstructured":"World Health Organization (WHO). IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Some N-Nitroso Compounds. Vol 17. France; 1978.","DOI":"10.1016\/0015-6264(79)90217-7"},{"key":"10.1016\/j.xphs.2021.04.021_bib0002","unstructured":"World Health Organization (WHO). Overall Evaluations of Carcinogenicity: an Updating of IARC Monographs Volumes 1 to 42. Lyon (FR); Vol 7., 1987."},{"key":"10.1016\/j.xphs.2021.04.021_bib0003","unstructured":"U.S. Department of Health and Human Services. 2017. 14th Report on carcinogens. Available at: https:\/\/ntp.niehs.nih.gov\/whatwestudy\/assessments\/cancer\/roc\/index.html#toc1. Accessed December 1,2020"},{"key":"10.1016\/j.xphs.2021.04.021_bib0004","unstructured":"European Medicines Agency. 2018. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU. Press Release. Available at: https:\/\/www.ema.europa.eu\/en\/news\/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0005","unstructured":"U.S. Food & Drug Administration. 2018. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. Press Release. Available at:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0006","unstructured":"U.S. Food & Drug Administration. 2018. FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm's already recalled products. Press Release. Available at:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-provides-update-its-ongoing-investigation-valsartan-products-and-reports-finding-additional. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0007","unstructured":"U.S. Food & Drug Administration. 2019. FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall. Press Release. Available at:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0008","unstructured":"World Health Organization (WHO). 2019. Information note: update on nitrosamine impurities. https:\/\/www.who.int\/news\/item\/20-11-2019-information-note-nitrosamine-impurities. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0009","unstructured":"U.S. Food & Drug Administration. 2019. Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. Statement. Available at:https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0010","unstructured":"European Medicines Agency. 2019. EMA to review ranitidine medicines following detection of NDMA. Press Release. Available at:https:\/\/www.ema.europa.eu\/en\/news\/ema-review-ranitidine-medicines-following-detection-ndma. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0011","unstructured":"U.S. Food & Drug Administration. 2020. Questions and answers: NDMA impurities in metformin products. Q&A. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/questions-and-answers-ndma-impurities-metformin-products. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0012","unstructured":"European Medicines Agency. 2019. EMA update on metformin diabetes medicines. Press Release. Available at: https:\/\/www.ema.europa.eu\/en\/news\/ema-update-metformin-diabetes-medicines. Accessed May 11, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0013","unstructured":"U.S. Food & Drug Administration. 2019. Laboratory analysis of ranitidine and nizatidine products. Laboratory Tests. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/laboratory-tests-ranitidine. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0014","unstructured":"European Medicines Agency. 2020. Suspension of ranitidine medicines in the EU. Press Release. Available at: https:\/\/www.ema.europa.eu\/en\/news\/suspension-ranitidine-medicines-eu. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0015","unstructured":"U.S. Food & Drug Administration. 2020. FDA requests removal of all ranitidine products (Zantac) from the market. Press Release. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requests-removal-all-ranitidine-products-zantac-market. Accessed December 1, 2020."},{"issue":"6","key":"10.1016\/j.xphs.2021.04.021_bib0016","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2165\/00003495-199346060-00004","article-title":"Safety profile of ranitidine. A review","volume":"46","author":"Wormsley","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.xphs.2021.04.021_bib0017","unstructured":"U.S. Food & Drug Administration. 2020. FDA works to mitigate shortages of rifampin and rifapentine after manufacturers find nitrosamine impurities. Update. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine. Accessed December 1, 2020."},{"issue":"10","key":"10.1016\/j.xphs.2021.04.021_bib0018","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/carcin\/13.10.1789","article-title":"Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes","volume":"13","author":"Yamazaki","year":"1992","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.xphs.2021.04.021_bib0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0304-3835(95)03786-V","article-title":"Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC","volume":"93","author":"Mirvish","year":"1995","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.xphs.2021.04.021_bib0020","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/carcin\/17.9.2029","article-title":"Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes","volume":"17","author":"Bellec","year":"1996","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.xphs.2021.04.021_bib0021","first-page":"1499","article-title":"Metabolism of N-nitrosodialkylamines by human liver microsomes","volume":"48","author":"Yoo","year":"1988","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.xphs.2021.04.021_bib0022","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1021\/tx0501334","article-title":"The structure of DNA dictates purine atom site selectivity in alkylation by primary diazonium ions","volume":"18","author":"Lu","year":"2005","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.xphs.2021.04.021_bib0023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0027-5107(90)90173-2","article-title":"Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents","volume":"231","author":"Beranek","year":"1990","journal-title":"Mutat Res"},{"issue":"5","key":"10.1016\/j.xphs.2021.04.021_bib0024","first-page":"391","article-title":"DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance","volume":"21","author":"Kyrtopoulos","year":"1997","journal-title":"Cancer Detect Prev"},{"issue":"7","key":"10.1016\/j.xphs.2021.04.021_bib0025","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/carcin\/15.7.1451","article-title":"Biochemical events during initiation of rat hepatocarcinogenesis","volume":"15","author":"Dragan","year":"1994","journal-title":"Carcinogenesis"},{"issue":"5955","key":"10.1016\/j.xphs.2021.04.021_bib0026","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/308201a0","article-title":"Mechanism of mutagenesis by O6-methylguanine","volume":"308","author":"Eadie","year":"1984","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.xphs.2021.04.021_bib0027","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1021\/bi00242a031","article-title":"Comparative mutagenesis of O6-methylguanine and O4-methylthymine in Escherichia coli","volume":"30","author":"Dosanjh","year":"1991","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2021.04.021_bib0028","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0027-5107(90)90162-W","article-title":"Site-specifically alkylated oligodeoxynucleotides: probes for mutagenesis, DNA repair and the structural effects of DNA damage","volume":"233","author":"Basu","year":"1990","journal-title":"Mutat Res"},{"issue":"3","key":"10.1016\/j.xphs.2021.04.021_bib0029","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/tx7003823","article-title":"Formation of formaldehyde adducts in the reactions of DNA and deoxyribonucleosides with alpha-acetates of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and N-nitrosodimethylamine (NDMA)","volume":"21","author":"Cheng","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.xphs.2021.04.021_bib0030","first-page":"1","article-title":"Formaldehyde, 2-butoxyethanol and 1-tert-butoxypropan-2-ol","volume":"88","year":"2006","journal-title":"IARC Monogr Eval Carcinog Risk Human"},{"issue":"8","key":"10.1016\/j.xphs.2021.04.021_bib0031","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1021\/tx700189c","article-title":"Development of liquid chromatography electrospray ionization tandem mass spectrometry methods for analysis of DNA adducts of formaldehyde and their application to rats treated with N-nitrosodimethylamine or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone","volume":"20","author":"Wang","year":"2007","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/j.xphs.2021.04.021_bib0032","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/tx000267b","article-title":"Microsome-mediated oxidation of N-nitrosodiethanolamine (NDELA), a bident carcinogen","volume":"15","author":"Loeppky","year":"2002","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.xphs.2021.04.021_bib0033","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/toxsci\/kfq121","article-title":"Radical mechanisms in nitrosamine- and nitrosamide-induced whole-genome gene expression modulations in Caco-2 cells","volume":"116","author":"Hebels","year":"2010","journal-title":"Toxicol Sci"},{"issue":"1 Suppl","key":"10.1016\/j.xphs.2021.04.021_bib0034","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0023677215570086","article-title":"Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice","volume":"49","author":"Tolba","year":"2015","journal-title":"Lab Anim"},{"issue":"12","key":"10.1016\/j.xphs.2021.04.021_bib0035","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/carcin\/6.12.1805","article-title":"The nature of microsomal N-nitrosodimethylamine demethylase and its role in carcinogen activation","volume":"6","author":"Hong","year":"1985","journal-title":"Carcinogenesis"},{"issue":"57","key":"10.1016\/j.xphs.2021.04.021_bib0036","first-page":"501","article-title":"Effect of ethanol on nitrosamine metabolism and distribution. Implications for the role of nitrosamines in human cancer and for the influence of alcohol consumption on cancer incidence","author":"Swann","year":"1984","journal-title":"IARC Sci Publ"},{"key":"10.1016\/j.xphs.2021.04.021_bib0037","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH M7 assessment and control of DNA Reactive (Mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk - Step 4. 2017. Available at: https:\/\/database.ich.org\/sites\/default\/files\/M7_R1_Guideline.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0038","unstructured":"European Medicines Agency. 2019. Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities. Press Release. Available at:https:\/\/www.ema.europa.eu\/en\/news\/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impurities. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0039","doi-asserted-by":"crossref","first-page":"k3851","DOI":"10.1136\/bmj.k3851","article-title":"Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: danish nationwide cohort study","volume":"362","author":"Pottegard","year":"2018","journal-title":"BMJ-British Med J"},{"issue":"3","key":"10.1016\/j.xphs.2021.04.021_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0041-008X(75)90255-0","article-title":"Formation of N-nitroso compounds: chemistry, kinetics, and in vivo occurrence","volume":"31","author":"Mirvish","year":"1975","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2021.04.021_bib0041","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1248\/cpb.47.819","article-title":"Reaction of secondary and tertiary amines with nitric oxide in the presence of oxygen","volume":"47","author":"Itoh","year":"1999","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.xphs.2021.04.021_bib0042","series-title":"Foye's Principles of Medicinal Chemistry","first-page":"747","article-title":"Agents affecting the renin-angiotensin pathway and calcium blockers","author":"Harrold","year":"2013"},{"issue":"41","key":"10.1016\/j.xphs.2021.04.021_bib0043","doi-asserted-by":"crossref","first-page":"12210","DOI":"10.1021\/ja0206644","article-title":"Mechanisms of Tetrazole formation by addition of azide to nitriles","volume":"124","author":"Himo","year":"2002","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.xphs.2021.04.021_bib0044","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1039\/JR9590002949","article-title":"591. Mechanism of the azide\u2013nitrite reaction. Part II","author":"Stedman","year":"1959","journal-title":"J Chem Soc"},{"key":"10.1016\/j.xphs.2021.04.021_bib0045","series-title":"Acyl compounds. U.S. Patent No. 5,399,578","author":"B\u00fchlmayer","year":"1995"},{"issue":"8","key":"10.1016\/j.xphs.2021.04.021_bib0046","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1021\/jm00112a031","article-title":"Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives","volume":"34","author":"Carini","year":"1991","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.xphs.2021.04.021_bib0047","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1021\/jm00074a018","article-title":"A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists","volume":"36","author":"Bernhart","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.xphs.2021.04.021_bib0048","series-title":"U.S. Patent No. 5,270,317","article-title":"N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present","author":"Bernhart","year":"1993"},{"key":"10.1016\/j.xphs.2021.04.021_bib0049","article-title":"Benzimidazole derivatives, their production and use. European patent No. 0459136 B1","author":"Naka","year":"1996","journal-title":"European Patent Office. Munich, Germany"},{"key":"10.1016\/j.xphs.2021.04.021_bib0050","series-title":"Alternative process for the preparation of losartan. U.S. Patent No. 7,923,566 B2","author":"Reddy","year":"2011"},{"issue":"2","key":"10.1016\/j.xphs.2021.04.021_bib0051","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.watres.2010.09.036","article-title":"Demonstration of 20 pharmaceuticals and personal care products (PPCPs) as nitrosamine precursors during chloramine disinfection","volume":"45","author":"Shen","year":"2011","journal-title":"WATER Res"},{"key":"10.1016\/j.xphs.2021.04.021_bib0052","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.watres.2015.07.045","article-title":"Effect of oxidation on amine-based pharmaceutical degradation and N-Nitrosodimethylamine formation","volume":"87","author":"Wang","year":"2015","journal-title":"WATER Res"},{"issue":"10","key":"10.1016\/j.xphs.2021.04.021_bib0053","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1016\/j.watres.2011.03.035","article-title":"Chloramination of nitrogenous contaminants (pharmaceuticals and pesticides): NDMA and halogenated DBPs formation","volume":"45","author":"Le Roux","year":"2011","journal-title":"WATER Res"},{"issue":"17","key":"10.1016\/j.xphs.2021.04.021_bib0054","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1016\/j.watres.2011.08.034","article-title":"NDMA formation kinetics from three pharmaceuticals in four water matrices","volume":"45","author":"Shen","year":"2011","journal-title":"WATER Res"},{"issue":"6","key":"10.1016\/j.xphs.2021.04.021_bib0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/carcin\/bgw034","article-title":"Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine","volume":"37","author":"Zeng","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.xphs.2021.04.021_bib0056","unstructured":"U.S. Food & Drug Administration. 2020. Final response letter from FDA CDER to valisure, LLC. Letter. Available at: https:\/\/www.regulations.gov\/document?D=FDA-2019-P-4281-0008. Accessed May 12, 2020."},{"issue":"1","key":"10.1016\/j.xphs.2021.04.021_bib0057","doi-asserted-by":"crossref","first-page":"PL1","DOI":"10.1016\/0024-3205(94)00578-8","article-title":"Photochemical generation of nitric oxide from nitro-containing compounds: possible relation to vascular photorelaxation phenomena","volume":"54","author":"Bauer","year":"1994","journal-title":"Life Sci"},{"issue":"22","key":"10.1016\/j.xphs.2021.04.021_bib0058","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1039\/c39900001598","article-title":"Facile formation of N-nitrosamines from bromonitromethane and secondary amines","author":"Challis","year":"1990","journal-title":"J Chem Soc Chem Commun"},{"issue":"58","key":"10.1016\/j.xphs.2021.04.021_bib0059","doi-asserted-by":"crossref","first-page":"11638","DOI":"10.1039\/C5CC03675E","article-title":"Copper(ii)-catalyzed oxidative N-nitrosation of secondary and tertiary amines with nitromethane under an oxygen atmosphere","volume":"51","author":"Sakai","year":"2015","journal-title":"Chem Commun"},{"key":"10.1016\/j.xphs.2021.04.021_bib0060","unstructured":"U.S. Food & Drug Administration. 2020. Mylan initiates voluntary nationwide recall of three lots of nizatidine capsules, USP, due to the detection of trace amounts of NDMA (N-Nitrosodimethylamine) impurity found in the active pharmaceutical ingredient manufactured by Solara active pharma Scien. Company Announcement. Available at:https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/mylan-initiates-voluntary-nationwide-recall-three-lots-nizatidine-capsules-usp-due-detection-trace. Accessed May 11, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0061","unstructured":"U.S. Food & Drug Administration. 2020. Amneal pharmaceuticals, LLC. Issues voluntary nationwide recall of nizatidine oral solution, 15mg\/mL, due to potential levels of N-nitrosodimethylamine (NDMA) impurity amounts above the levels established by FDA. Company Announcement. Available at: https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-nizatidine-oral-solution-15-mgml-due. Accessed May 11, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0062","unstructured":"European Medicines Agency. 2019. Update on nitrosamine impurities: EMA continues to work to prevent impurities in medicines. Update. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/update-nitrosamine-impurities-ema-continues-work-prevent-impurities-medicines_en.pdf. Accessed May 11, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0063","unstructured":"Health Canada. 2020. Certain Metformin diabetes drugs recalled due to the presence or possible presence of NDMA. Information update. Available at:https:\/\/healthycanadians.gc.ca\/recall-alert-rappel-avis\/hc-sc\/2020\/72287a-eng.php. Accessed May 11, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0064","unstructured":"U.S. Food & Drug Administration. 2019. FDA updates and press announcements on NDMA in metformin. Press announcement. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-ndma-metformin. Accessed May 11, 2020]"},{"issue":"24","key":"10.1016\/j.xphs.2021.04.021_bib0065","doi-asserted-by":"crossref","first-page":"13403","DOI":"10.1039\/C9RA01641D","article-title":"A combined experimental and density functional theory study of metformin oxy-cracking for pharmaceutical wastewater treatment","volume":"9","author":"Badran","year":"2019","journal-title":"RSC Adv"},{"key":"10.1016\/j.xphs.2021.04.021_bib0066","unstructured":"U.S. Food & Drug Administration. 2019. Combined N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurity assay by GC\/MS-headspace. Test method. Available at:https:\/\/www.fda.gov\/media\/117843\/download. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0067","unstructured":"U.S. Food & Drug Administration. 2019. GC\/MS headspace method for detection of NDMA in valsartan drug substance and drug products. Test method. Available at: https:\/\/www.fda.gov\/media\/115965\/download. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0068","unstructured":"Health Canada. 2019. Impurities found in certain angiotensin II receptor blocker (ARB) products, also known as Sartans. Information update. Available at:https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/information-health-product\/drugs\/angiotensin-receptor-blocker.html. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0069","unstructured":"U.S. Food & Drug Administration. 2018. Combined direct injection N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurity assay by GC\/MS. Test method. Available at:https:\/\/www.fda.gov\/media\/117807\/download. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0070","unstructured":"The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2019. LC-MS\/MS method for LOSARTAN potassium. Test method. Available at: https:\/\/www.edqm.eu\/sites\/default\/files\/de_lgl_losartan_method_parameters_nmba_lcms.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0071","unstructured":"The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2019. Method for the determination of NDMA and NDEA by LC-MS\/MS in Sartan containing film coated tablets. Test method. Available at:https:\/\/www.edqm.eu\/sites\/default\/files\/method_for_the_determination_of_ndma_and_ndea_by_lc-ms-ms_in_sartan_containing_film_coated_tablets.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0072","unstructured":"The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2018. Test method for the determination of NDMA by LC\/MS\/MS in valsartan finished products. Test method. Available at: https:\/\/www.edqm.eu\/sites\/default\/files\/omcl-method-determination-ndma-valsartan-cvua-september2018.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0073","unstructured":"The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2019. Determination of NDMA and NDEA in SARTAN drug substances by HPLC\/UV. Test method. Available at: https:\/\/www.edqm.eu\/sites\/default\/files\/method_19a0416-01_ndma_and_ndea_in_sartan_by_hplc-uv_-_ansm.pdf. Accessed December 1, 2020."},{"issue":"4","key":"10.1016\/j.xphs.2021.04.021_bib0074","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1208\/s12248-020-00473-w","article-title":"A cautionary tale: quantitative LC-HRMS analytical procedures for the analysis of N-Nitrosodimethylamine in metformin","volume":"22","author":"Yang","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2021.04.021_bib0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jpba.2019.05.022","article-title":"The contamination of valsartan and other Sartans, part 1: new findings","volume":"172","author":"Soergel","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2021.04.021_bib0076","unstructured":"Taiwan Food and Drug Administration. 2020. Method of test for nitrosamines in medicines. Test method. Available at: https:\/\/www.fda.gov.tw\/ENG\/siteList.aspx?sid=10360. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0077","unstructured":"The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2019. LC-MS\/MS method for the determination of NDEA and NMDA in valsartan, irbesartan and losartan APIs and finished dosage forms (developed on a AB Sciex QTrap 5500). Test method. Available at: https:\/\/www.edqm.eu\/sites\/default\/files\/medias\/fichiers\/Sartans\/de-by-lc-ms_ls.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0078","unstructured":"U.S. Food & Drug Administration. 2019. Combined direct injection N-nitrosodimethylamine (NDMA), N-nitrosodiethylamine (NDEA), N-nitrosoethylisopropylamine (NEIPA), N-nitrosodiisopropylamine (NDIPA), and N-nitrosodibutylamine (NDBA) impurity assay by GC-MS\/MS. Test method. Available at: https:\/\/www.fda.gov\/media\/123409\/download. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0079","unstructured":"The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2019. Nitrosamines by GC-MS\/MS. Test method. Available at:https:\/\/www.edqm.eu\/sites\/default\/files\/medias\/fichiers\/OMCL\/omcl_31_pv_171_nitrosamine_by_gc_ms_ms.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0080","unstructured":"U.S. Food & Drug Administration. 2020. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of NDMA in metformin drug substance and drug product. Test method. Available at: https:\/\/www.fda.gov\/media\/134914\/download. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0081","unstructured":"The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2019. GC-MS method \u00b4NDMA in Metformin-HCl API and finished dosage forms\u00b4 (Shimadzu GCMS QP 2020plus). Test method. Available at: https:\/\/www.edqm.eu\/sites\/default\/files\/medias\/fichiers\/OMCL\/omcl_method_parameters_ndma_api.fdf_metformin_de-by.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0082","unstructured":"The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2020. GC-MS\/MS method for the detection and determination of nitrosamine impurities in medicinal products. Test method. Available at:https:\/\/www.edqm.eu\/sites\/default\/files\/medias\/fichiers\/Nitrosamines\/omcl_cvua_karlsruhe_gcmsms_method_for_ndma_determination_in_metformin_ds_ad_dp_3mar.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0083","unstructured":"Health Sciences Authority. 2020. Determination of N-nitrosodimethylamine (NDMA) in metformin products by HRAM-GCMS. Test method. Available at:https:\/\/www.hsa.gov.sg\/docs\/default-source\/announcements\/safety-alerts\/determination-of-ndma-in-metformin-products-by-hram-gcms.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0084","unstructured":"U.S. Food & Drug Administration. 2019. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of NDMA in ranitidine drug substance and drug product. Test method. Available at: https:\/\/www.fda.gov\/media\/130801\/download. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0085","unstructured":"U.S. Food & Drug Administration. 2019. Liquid chromatography-tandem mass spectrometry (LC-MS\/MS) method for the determination of NDMA in ranitidine drug substance and solid dosage drug product. Test method. Available at: https:\/\/www.fda.gov\/media\/131868\/download. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113582","article-title":"HS-SPME-GC-MS as an alternative method for NDMA analysis in ranitidine products","volume":"191","author":"Alshehri","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2021.04.021_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113460","article-title":"Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography\u2013tandem mass spectrometry","volume":"189","author":"Lim","year":"2020","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2021.04.021_bib0088","unstructured":"The United State Pharmacopeia. 2020. <1469> Nitrosamine impurities. General Chapter Prospectus. Available at: https:\/\/www.uspnf.com\/notices\/nitrosamine-impurities-gc-prospectus-20200424. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0089","unstructured":"The Association of Southeast Asian Nations (ASEAN). 2016. ASEAN common technical dossier (ACTD). Available at: https:\/\/asean.org\/storage\/2017\/03\/68.-December-2016-ACTD.pdf. Accessed December 1, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0090","unstructured":"European Medicines Agency. 2019. EMA advises companies on steps to take to avoid nitrosamines in human medicines. Press Release. Available at: https:\/\/www.ema.europa.eu\/en\/news\/ema-advises-companies-steps-take-avoid-nitrosamines-human-medicines. Accessed May 19, 2020."},{"key":"10.1016\/j.xphs.2021.04.021_bib0091","unstructured":"European Medicines Agency. 2020. Assessment report: nitrosamine impurities in human medicinal products procedure number: EMEA\/H\/A-5(3)\/1490. Available at:https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/referral-procedures\/nitrosamine-impurities. Accessed December 1, 2020."},{"issue":"9","key":"10.1016\/j.xphs.2021.04.021_bib0092","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","article-title":"Pathways for N-nitroso compound formation: secondary amines and beyond","volume":"24","author":"L\u00f3pez-Rodr\u00edguez","year":"2020","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.xphs.2021.04.021_bib0093","unstructured":"U.S. Food & Drug Administration. 2019. FDA updates table of interim limits for nitrosamine impurities in ARBs. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan#interimlimits2. Accessed May 19, 2020."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921002446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921002446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:35:42Z","timestamp":1758360942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921002446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0022354921002446"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.04.021","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}